MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
expense
$109,118K
Accounts receivable
-$41,314K
Issuance of common stock
from exercise of...
$6,803K
Depreciation and
amortization
$36,199K
Inventory
-$27,953K
Accrued compensation
and other related...
$7,647K
Amortization of right-of-use
assets
$7,617K
Fair value
adjustments on contingent...
-$1,407K
Other noncurrent
liabilities
$1,396K
Rou assets
impairment due to...
$1,253K
Asset and lease
impairment charges
$814K
Deferred revenue
$746K
Other noncurrent
assets
-$689K
Net cash provided by
(used in) operating...
$136,050K
Net cash provided by
financing activities
$6,803K
Effect of exchange rate
changes on cash and cash...
$484K
Canceled cashflow
$100,103K
Net increase
(decrease) in cash and cash...
$129,899K
Canceled cashflow
$13,438K
Net loss
-$43,544K
Other receivables
$34,874K
Operating lease liability
-$10,310K
Accrued expenses and
other current...
-$5,153K
Prepaid expenses and
other current assets
$2,343K
Accounts payable
-$2,126K
Other
-$1,753K
Proceeds from maturities
of marketable...
$125,200K
Net cash (used in)
provided by investing...
-$13,438K
Canceled cashflow
$125,200K
Purchase of marketable
securities
$123,435K
Asset acquisition,
net
$9,268K
Purchases of property and
equipment
$5,935K
Back
Back
Cash Flow
source: myfinsight.com
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)